HWP
BIO icon

Highline Wealth Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Highline Wealth Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.75K Sell
23
-4
-15% -$1.14K ﹤0.01% 761
2026
Q1 		$7.53K Buy
+27
New +$7.78K ﹤0.01% 567

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Highline Wealth Partners's BIO Position: Q2 2026 in Review

Highline Wealth Partners reduced its Bio-Rad Laboratories Class A (BIO) stake by 15% in Q2 2026, selling an estimated $1.14K and leaving 23 shares worth $6.75K. The position accounts for ﹤0.01% of the portfolio, ranked #761.

Highline Wealth Partners first reported a position in BIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.53K in Q1 2026. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Highline Wealth Partners held 23 shares of Bio-Rad Laboratories Class A worth $6.75K as of Q2 2026.
  • Highline Wealth Partners sold 4 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $1.14K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Highline Wealth Partners's portfolio in Q2 2026, its #761 holding.
  • Highline Wealth Partners first reported a position in Bio-Rad Laboratories Class A in Q1 2026 and has held it in 2 quarters since.
  • Highline Wealth Partners's Bio-Rad Laboratories Class A position peaked at $7.53K in Q1 2026.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.